Table 3 Active trials involving peptide and tumor lysate-derived vaccines
NCT | Phase | Intervention | Target population | Location | Sample size | Key outcomes |
|---|---|---|---|---|---|---|
NCT01903330 | Phase II | ERC1671 (tumor-derived cells and cell lysate) combined with GM-CSF and cyclophosphamide to stimulate the immune response, with bevacizumab, vs placebo injection with bevacizumab | Recurrent glioblastoma or gliosarcoma | USA | 84 | OS, PFS, immune response, adverse events |
NCT02287428 | Phase I | NeoVax (personalized neoantigen vaccine from autologous tumor lysate) with pembrolizumab with or without standard therapy | Newly diagnosed glioblastoma | USA | 56 | Safety, adverse events, number of actionable peptides, feasibility of vaccine administration |
NCT03018288 | Phase II | RT/TMZ plus pembrolizumab, with or without HSPPC-96 (heat shock protein peptide complex-96) peptide vaccine | Newly diagnosed glioblastoma | USA | 90 | OS |
NCT03149003 | Phase III | WT1 antigen-based peptide vaccine (DSP-7888) with concurrent bevacizumab vs bevacizumab alone | Recurrent or progressive glioblastoma with HLA-A2 positivity | Multiple countries | 236 | DLT, OS, PFS, adverse events |
NCT03223103 | Phase I | Personalized vaccine containing synthetic long peptides adjusted to the patient's tumor, with poly:ICLC and tumor-treating fields | Newly diagnosed glioblastoma immediately after TMZ/RT | USA | 13 | DLT, OS, PFS, ORR |
NCT03382977 | Phase I/IIa | Use of a pp65 peptide-containing vaccine, administered with GM-CSF for immune response improvement | Recurrent glioblastoma | USA | 38 | DLT, immunogenicity, anti-CMV immunity, Treg and myeloid changes, OS, PFS |
NCT03650257 | Phase II | gp96 vaccine received after TMZ/RT | Newly diagnosed high-grade glioma | China | 150 | OS, PFS, T cell changes |
NCT03665545 | Phase I/II | IMA950, a standardized peptide vaccine, plus poly-ICLC for immunogenicity | Recurrent glioblastoma | Switzerland | 24 | Adverse events, PFS, OS, TIL density, T cell responses |
NCT04013672 | Phase II | Pembrolizumab, with SurVaxM, sargramostim, and montanide ISA 51 in combination | Recurrent glioblastoma | USA | 40 | PFS, safety, and tolerability |
NCT04116658 | Phase Ib/IIa | EO2401 (therapeutic peptide vaccine based on tumor-associated antigens and microbiome-derived peptides) with and without nivolumab and bevacizumab | Recurrent or progressive glioblastoma with HLA-A2 positivity | Multiple countries | 52 | Safety and tolerability, OS, immunogenicity |
NCT04280848 | Phase I/II | Peptide vaccine with telomerase-derived antigens, with Montanide ISA 51 (vaccine adjuvant) | Recurrent or progressive, MGMT-unmethylated glioblastoma | France | 28 | Immunogenicity via T cell responses |
NCT04642937 | Phase I | Combination therapy with anti-CD200AR ligand, imiquimod, and GBM6-AD tumor lysate vaccine | Recurrent glioblastoma | USA | 24 | MTD, adverse events, OS, PFS |
NCT04808245 | Phase I | Peptide vaccine against H3K27M antigens, along with atezolizumab and imiquimod | Newly diagnosed H3K27M-mutated gliomas | Germany | 15 | Toxicity, immunogenicity, PFS, OS |
NCT04842513 | Phase I | Vaccine (XS15) containing specific immunomodulatory proteins after standard of care | Newly diagnosed IDH wt, HLA-A2 positive, MGMT-methylated glioblastoma after resection | Germany | 15 | Adverse events, immunogenicity changes |